期刊文献+

阿利吉仑联合雷米普利治疗轻中度原发性高血压的疗效观察 被引量:1

Observation on efficacy of aliskiren combined with ramipril in the treatment of mild to moderate essential hypertension
下载PDF
导出
摘要 目的探讨阿利吉仑联合雷米普利治疗轻中度原发性高血压的临床疗效。方法选取轻中度原发性高血压患者102例(2017年11月~2018年6月),按随机数字表分为研究组(n=51)与对照组(n=51)。常规干预基础上对照组予雷米普利治疗,研究组在对照组基础上加用阿利吉仑治疗,疗程均为8周。统计两组治疗前及疗程结束后血压[舒张压(DBP)、收缩压(SBP)]、生活质量(SF-36)、不良反应。结果疗程结束后,两组SBP、DBP低于治疗前,且研究组低于对照组(P<0.001),两组SF-36分值较治疗前增高,且研究组高于对照组(P<0.001);研究组不良反应发生率(13.73%)与对照组(9.80%)比较差异无统计学意义(P>0.05)。结论雷米普利联合阿利吉仑治疗轻中度原发性高血压,可有效调节血压,改善患者生活质量,且不会增加不良反应发生风险,安全性较好。 Objective To investigate the clinical effects of aliskiren combined with ramipril on the treatment of mild to moderate essential hypertension.Methods A total of 102 patients with mild to moderate essential hypertension admitted to hospital from November 2017 to June 2018 were enrolled in the study,and all patients were divided into study group(n=51)and control group(n=51)according to randomized digital table.On the basis of routine intervention,the control group were treated with ramipril,and the study group were given aliskiren based on the control group.Both groups were treated for 8 weeks.And then,blood pressure[diastolic blood pressure(DBP),systolic blood pressure(SBP)],quality of life(SF-36),and adverse reactions were counted before and after the treatment.Results After the course of treatment,SBP and DBP in the two groups were lower than those before treatment,and those in the study group were lower than those in the control group(P<0.001);the SF-36 scores of the two groups were higher than those before treatment,and that of the study group was higher than that of the control group(P<0.001);the incidence of adverse reactions in the study group was 13.73%,and that the control group was 9.80%,difference was not statistically significant between the two groups(P>0.05).Conclusion Ramipril combined with aliskiren in the treatment of mild to moderate essential hypertension can effectively regulate the blood pressure of patients and improve their quality of life without increasing the risk of adverse reactions,which has high safety.
作者 孙前进 邹坤庆 马玉侠 SUN Qianjin;ZOU Kunqing;MA Yuxia(Department of Internal Medicine One,The Second People’s Hospital of Jiyuan,Jiyuan 459000,China)
出处 《右江医学》 2019年第4期275-278,共4页 Chinese Youjiang Medical Journal
关键词 阿利吉仑 雷米普利 原发性高血压 轻中度 血压控制 生活质量 aliskiren ramipril essential hypertension mild to moderate blood pressure control quality of life
  • 相关文献

参考文献8

二级参考文献69

  • 1陈绍行,郭冀珍,吴顺娣,陆旭辉,陶波,林伯贤.厄贝沙坦单用及合用治疗轻、中度原发性高血压60例[J].中国新药与临床杂志,2004,23(10):651-654. 被引量:9
  • 2韩运峰,苏诚坚,区碧如.感觉神经损伤性盐敏感性高血压大鼠新模型的建立及其细胞内游离钙的变化[J].岭南心血管病杂志,2003,9(2):115-120. 被引量:19
  • 3许柳青,叶琼,许昌声,王华军,吴可贵.p38丝裂素活化蛋白激酶介导自发性高血压大鼠血管平滑肌细胞增殖[J].中华高血压杂志,2007,15(9):759-763. 被引量:5
  • 4AzharRashikh,Shibli JameelAhmad,Krishna KolappaPillai,Abul KalamNajmi.Aliskiren as a novel therapeutic agent for hypertension and cardio‐renal diseases[J]. Journal of Pharmacy and Pharmacology . 2012 (4)
  • 5Alice V. Stanton,Alan H. Gradman,Roland E. Schmieder,Juerg Nussberger,Ramesh Sarangapani,Margaret F. Prescott.Aliskiren Monotherapy Does Not Cause Paradoxical Blood Pressure Rises: Meta-Analysis of Data From 8 Clinical Trials[J]. Hypertension . 2010 (1)
  • 6Morgado Manuel P,Rolo Sandra A,Castelo-Branco Miguel.Efficacy of aliskiren/hydrochlorothiazide combination for the treatment of hypertension: a meta-analytical approach. The open cardiovascular medicine journal . 2011
  • 7Andrew D. Oxman,Gordon H. Guyatt.Validation of an index of the quality of review articles. Journal of Clinical Epidemiology . 1991
  • 8Gao Dengfeng,Ning Ning,Niu Xiaolin,Wei Jin,Sun Ping,Hao Guanghua.Aliskiren vs. angiotensin receptor blockers in hypertension: meta-analysis of randomized controlled trials. American journal of hypertension . 2011
  • 9Chen Y,Meng L,Shao H, et al.Aliskiren vs. other antihypertensive drugs in thetreatment of hypertension: a meta-analysis.. Hypertension Research . 2013
  • 10Zhenfeng Zheng,Huilan Shi,Junya Jia,Dong Li,Shan Lin.A systematic review and meta-analysis of aliskiren and angiotension receptor blockers in the management of essential hypertension. Journal of the renin-angiotensin-aldosterone system : JRAAS . 2010

共引文献115

同被引文献14

引证文献1

二级引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部